Pharmacokinetics of midazolam and 1'-hydroxymidazolam in Chinese with different CYP3A5 genotypes.

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Drug Metabolism And Disposition

• Publication date

  2002-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1124/DMD.30.12.1491PMID 12433824
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The human cytochrome P450 CYP3 locus: assignment to chromosome 7q22-qter

  2004cited by this paper
• Dissecting the function of cytochrome P450.

  2003cited by this paper
• Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism.

  2002influential reference
• Intergenic mRNA Molecules Resulting fromtrans-Splicing*

  2002cited by this paper
• Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and *6, in a Japanese population.

  2002influential reference
• Genetic polymorphism of cytochrome P450 3A5 in Chinese.

  2001influential reference
• Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression

  2001influential reference
• Cloning and tissue distribution of a novel human cytochrome p450 of the CYP3A subfamily, CYP3A43.

  2001cited by this paper
• cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450.

  2001influential reference
• The genetic determinants of the CYP3A5 polymorphism.

  2001influential reference
• The human cytochrome P450 3A locus. Gene evolution by capture of downstream exons.

  2000cited by this paper
• Two linked mutations in transcriptional regulatory elements of the CYP3A5 gene constitute the major genetic determinant of polymorphic activity in humans.

  2000cited by this paper
• Relationship between hepatic cytochrome P450 3A content and activity and the disposition of midazolam administered orally.

  1998cited by this paper
• Sensitive assay for midazolam and its metabolite 1'-hydroxymidazolam in human plasma by capillary high-performance liquid chromatography.

  1998cited by this paper
• Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein?

  1996influential reference
• P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

  1996cited by this paper
• Bimodal distribution of renal cytochrome P450 3A activity in humans.

  1996cited by this paper
• Substrates of human hepatic cytochrome P450 3A4.

  1995cited by this paper
• Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver.

  1994cited by this paper
• Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.

  1994cited by this paper
• Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily.

  1994cited by this paper
• Midazolam is metabolized by at least three different cytochrome P450 enzymes.

  1994influential reference
• Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation.

  1994cited by this paper
• Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control.

  1993cited by this paper
• Expression of cytochrome P450 3A in amphibian, rat, and human kidney.

  1992cited by this paper
• Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3).

  1990cited by this paper
• Identification of a polymorphically expressed member of the human cytochrome P-450III family.

  1989cited by this paper
• Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver. cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine.

  1989cited by this paper

• Deconvoluting Gut Versus Liver Cytochrome P450 3A4 Function: Drug Probes, Biomarkers, and Tissue Biopsy

  2026cites this paper
• Pharmacokinetics of CYP2C19- and CYP3A4-Metabolized Drugs in Cirrhosis Using a Whole-Body PBPK Approach

  2025cites this paper
• Extrapolation of Midazolam Disposition in Neonates Using Physiological‐Based Pharmacokinetic/Pharmacodynamic Modeling

  2025cites this paper
• Drug-Drug Interactions Between COVID-19 Treatments and Psychotropic Medications: An Updated Study

  2023cites this paper
• PharmVar GeneFocus: CYP3A5

  2022cites this paper
• Pharmacogenetics in Primary Headache Disorders

  2022cites this paper
• Sources of Interindividual Variability.

  2021cites this paper
• Sedatives and hypnotics

  2020cites this paper
• Quantitative Prediction of CYP3A4‐ and CYP3A5‐Mediated Drug Interactions

  2020cites this paper
• Midazolam Dose Optimization in Critically Ill Pediatric Patients With Acute Respiratory Failure: A Population Pharmacokinetic-Pharmacogenomic Study

  2019cites this paper
• Landscape of CYP3A5 Variants in Central-Eastern and South European Populations

  2019cites this paper
• Validation of a 3-h Sampling Interval to Assess Variability in Cytochrome P450 3A Phenotype and the Impact of Induction and Mechanism-Based Inhibition Using Midazolam as a Probe Substrate

  2019cites this paper
• Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach

  2018cites this paper
• Assessment of inter-racial variability in CYP3A4 activity and inducibility among healthy adult males of Caucasian and South Asian ancestries

  2018cites this paper
• Chapter 58 – Pharmacogenomics

  2017cites this paper
• The Benefit and Future of Pharmacogenetics

  2017cites this paper
• Pharmacokinetics, pharmacodynamics, and tolerability of USL261, midazolam nasal spray: Randomized study in healthy geriatric and non-geriatric adults

  2017cites this paper
• Benzodiazepines, Age-Related Pharmacological Changes, and Risk of Falls in Older Adults

  2016cites this paper
• Relationships between Endogenous Plasma Biomarkers of Constitutive Cytochrome P450 3A Activity and Single‐Time‐Point Oral Midazolam Microdose Phenotype in Healthy Subjects

  2016cites this paper
• Generalized Multifactor Dimensionality Reduction (GMDR) Analysis of Drug-Metabolizing Enzyme-Encoding Gene Polymorphisms may Predict Treatment Outcomes in Indian Breast Cancer Patients

  2016cites this paper
• Sufentanil and midazolam dosing and pharmacogenetic factors in pediatric analgosedation and withdrawal syndrome.

  2016cites this paper
• Pharmacogenetic Aspects of Anesthetic and Analgesic Agents

  2015cites this paper
• بررسی ارتباط بین پلی مورفیسم در ژن CYP3A5 با سرطان مثانه

  2015cites this paper
• Limited Sampling Strategy of Partial Area Under the Concentration–Time Curves to Estimate Midazolam Systemic Clearance for Cytochrome P450 3A Phenotyping

  2015influential citation
• Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration

  2015cites this paper
• Analysis of the CYP3A4*1B gene variant in an Iranian Population: Pilot base study

  2015cites this paper
• Association Study of Polymorphism in CYP3A5 Gene with Bladder Cancer

  2015cites this paper
• DMD057000 1163..1173

  2014cites this paper
• Sources of interindividual variability.

  2014cites this paper
• Pharmacogenomics in Anesthesia

  2014cites this paper
• Relative Contributions of Cytochrome CYP 3 A 4 Versus CYP 3 A 5 for CYP 3 A-Cleared Drugs Assessed In Vitro Using a CYP 3 A 4-Selective Inactivator ( CYP 3 cide ) s

  2014cites this paper
• INTERVENTION OF PHARMACOGENETIC PROFILING IN THERAPEUTICS OF KASHMIRI POPULATION, A LESSON LEARNED FROM CYP3A5*3 VARIANT

  2014cites this paper
• Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide)

  2014cites this paper
• Significant role of CYP450 genetic variants in cyclophosphamide based breast cancer treatment outcomes: a multi-analytical strategy.

  2014cites this paper
• Genetic polymorphisms associated with antiepileptic metabolism.

  2014cites this paper
• A Nanogram Dose of the CYP3A Probe Substrate Midazolam to Evaluate Drug Interactions

  2013cites this paper
• Role of pharmacogenetics on adjuvant chemotherapy-induced neutropenia in Chinese breast cancer patients

  2013cites this paper
• Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping

  2013cites this paper
• Effects of CYP3A5 and CYP2D6 genetic polymorphism on the pharmacokinetics of diltiazem and its metabolites in Chinese subjects.

  2013cites this paper
• Differences in Cytochrome P450-Mediated Pharmacokinetics Between Chinese and Caucasian Populations Predicted by Mechanistic Physiologically Based Pharmacokinetic Modelling

  2013cites this paper
• CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin.

  2013cites this paper
• PharmGKB summary: very important pharmacogene information for CYP3A5.

  2012cites this paper
• Comparative Study between Conventional and Thermoreversible Mucoadhesive Nasal Gels of Midazolam Hydrochloride

  2012cites this paper
• In Vivo CYP3A4 Activity, CYP3A5 Genotype, and Hematocrit Predict Tacrolimus Dose Requirements and Clearance in Renal Transplant Patients

  2012cites this paper
• Pharmacogenetics and anesthetic drugs.

  2012cites this paper
• Amlodipine, clopidogrel and CYP3A5 genetic variability: effects on platelet reactivity and clinical outcomes after percutaneous coronary intervention

  2012cites this paper
• Effect of Quercetin on CYP3A Activity in Chinese Healthy Participants

  2012cites this paper
• "In-vivo" phenotyping of CYP3A using midazolam as probe drug : development of novel approaches based on highly sensitive LC-MS/MS methods

  2011cites this paper
• Characterization of mucoadhesive nasal gels containing midazolam hydrochloride prepared from Linum usitatissimum L. mucilage

  2011cites this paper
• Genetically Polymorphic Cytochrome P450s and Transporters and Personalized Antimicrobial Chemotherapy

  2011cites this paper
• Development and Characterization of Mucoadhesive In Situ Nasal Gel of Midazolam Prepared with Ficus carica Mucilage

  2010cites this paper
• THE ROLE OF CYP 3 A 4 / 5 IN ALPRAZOLAM METABOLISM

  2010cites this paper
• Influence of CYP3A5 and MDR1 Genetic Polymorphisms on Urinary 6β‐Hydroxycortisol/Cortisol Ratio After Grapefruit Juice Intake in Healthy Chinese

  2010cites this paper
• The role of CYP3A4/5 in alprazolam metabolism

  2010cites this paper
• Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal breast cancer patients

  2009cites this paper
• Polymorphisms of drug-metabolizing enzymes (GST, CYP2B6 and CYP3A) affect the pharmacokinetics of thiotepa and tepa.

  2009cites this paper
• Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans

  2009cites this paper
• Pharmacogenomics of CYP3A: considerations for HIV treatment.

  2009cites this paper
• The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test

  2009cites this paper
• Association of genotypes of the CYP3A cluster with midazolam disposition in vivo

  2009cites this paper
• Validation of a new HPLC method for determination of midazolam and its metabolites: application to determine its pharmacokinetics in human and measure hepatic CYP3A activity in rabbits.

  2009cites this paper
• Polymorphism of human cytochrome P450 enzymes and its clinical impact

  2009cites this paper
• CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole

  2009cites this paper
• Impact of CYP3A5 and CYP3A4 gene polymorphisms on dose requirement of calcineurin inhibitors, cyclosporine and tacrolimus, in renal allograft recipients of North India

  2009cites this paper
• Pharmacogenetics of anesthetics

  2008cites this paper
• Benzodiazepine metabolism: an analytical perspective.

  2008cites this paper
• EFFECTS OF CYTOCHROME P450 ENZYME INHIBITORS ON THE PHARMACOKINETICS OF NONSTEROIDAL ANTI-INFLAMMATORY DRUGS AND VENLAFAXINE

  2008cites this paper
• Inflammation and CYP3A4-mediated drug metabolism in advanced cancer: impact and implications for chemotherapeutic drug dosing

  2008cites this paper
• Pharmacogenetics and Pharmacokinetics in high-dose alkylating chemotherapy

  2008cites this paper
• Effects of Cytochrome P450 Enzyme Inhibitors on the Pharmacokinetics of Nonsteroidal Anti-inflammatory Drugs and Venlafaxine

  2008cites this paper
• Factors Affecting Pharmacokinetic Variability of Imatinib Mesylate (Gleevec, STI-571)

  2008cites this paper
• Genetic association analysis of polymorphisms in four cytochrome P450 genes, the MDR1 gene and treatment-outcome in Xhosa schizophrenia patients

  2007cites this paper
• Identifying drugs needing pharmacogenetic monitoring in a Korean hospital.

  2007cites this paper
• Effects of genetic polymorphism of cytochrome P450 enzymes on the pharmacokinetics of benzodiazepines

  2007cites this paper
• The CYP3A4*18 Allele, the Most Frequent Coding Variant in Asian Populations, Does Not Significantly Affect the Midazolam Disposition in Heterozygous Individuals

  2007cites this paper
• CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir

  2007cites this paper
• Theoretical Biology and Medical Modelling Open Access Dynamically Simulating the Interaction of Midazolam and the Cyp3a4 Inhibitor Itraconazole Using Individual Coupled Whole-body Physiologically-based Pharmacokinetic (wb-pbpk) Models

  2007cites this paper
• Impact of the CYP3A5 genotype on midazolam pharmacokinetics and pharmacodynamics during intensive care sedation

  2007cites this paper
• CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer

  2007cites this paper
• Overview of Pharmacogenetics

  2007cites this paper
• Different roles of pummelo furanocoumarin and cytochrome P450 3A5*3 polymorphism in the fate and action of felodipine.

  2007cites this paper
• Genetic polymorphisms of drug‐metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population

  2007cites this paper
• Physiologic effects of cytochrome P450 3A activity

  2007influential citation
• MDR1 Single Nucleotide Polymorphisms Predict Response to Vinorelbine-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer

  2007cites this paper
• Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity.

  2007cites this paper
• Genetic variants of CYP3A5, CYP2D6, SULT1A1, UGT2B15 and tamoxifen response in postmenopausal patients with breast cancer

  2007cites this paper
• Influence of CYP3A5 Genotype on the Pharmacokinetics and Pharmacodynamics of the Cytochrome P4503A Probes Alfentanil and Midazolam

  2007cites this paper
• Increased risk of atherothrombotic events associated with cytochrome P450 3A5 polymorphism in patients taking clopidogrel

  2006cites this paper
• SELECTIVE METABOLISM OF VINCRISTINE IN VITRO BY CYP3A5

  2006cites this paper
• Significance of the Minor Cytochrome P450 3A Isoforms

  2006cites this paper
• Influence of CYP3A5 genetic polymorphism on cyclosporine A metabolism and elimination in Chinese renal transplant recipients

  2006cites this paper
• CYP3A5 genotype has significant effect on quinine 3-hydroxylation in Tanzanians, who have lower total CYP3A activity than a Swedish population

  2006cites this paper
• Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5

  2006cites this paper
• FACTORS INFLUENCING MIDAZOLAM HYDROXYLATION ACTIVITY IN HUMAN LIVER MICROSOMES

  2006cites this paper
• Clinical implications of CYP3A polymorphisms

  2006cites this paper
• Identification and characterization of CYP3A4*20, a novel rare CYP3A4 allele without functional activity

  2006cites this paper
• Maribavir Pharmacokinetics and the Effects of Multiple-Dose Maribavir on Cytochrome P450 (CYP) 1A2, CYP 2C9, CYP 2C19, CYP 2D6, CYP 3A, N-Acetyltransferase-2, and Xanthine Oxidase Activities in Healthy Adults

  2006cites this paper
• Small Interfering RNA-Mediated Silencing of Cytochrome P450 3A4 Gene

  2006cites this paper
• Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of alprazolam in healthy subjects

  2006cites this paper
• Clinical Pharmacokinetics of Docetaxel

  2006cites this paper